Searchable abstracts of presentations at key conferences in endocrinology

ea0090s9.1 | Pitfalls in osteoporosis treatment transition | ECE2023

Denosumab discontinuation

Langdahl Bente

Denosumab is an effective treatment of osteoporosis that leads to substantial increases in bone mass and clinically important reductions in fracture risk with few side effects. Most patients should continue treatment; however, some patients may need to discontinue treatment due to co-morbidities or side effects. Furthermore, some patients want to discontinue treatment because of normal or near-normal BMD and absence of fractures after years on treatment. Unlike bisphosphonates...

ea0070s2.1 | Osteoporosis and fracture prediction | ECE2020

Risk of fractures following discontinuation of denosumab – and how to handle it

Langdahl Bente L

Denosumab (DMAB) discontinuation is characterized by an increase in bone turnover and a rapid bone loss. These changes are associated with an increased risk of multiple vertebral fractures (VFx). Prevalent VFx, longer duration of therapy, greater gain in hip BMD during DMAB, and greater loss of hip BMD after DMAB were identified as risk factors for multiple VFx following DMAB cessation in a retrospective analysis of the FREEDOM Extension Study. Case series have indicated that ...

ea0022p192 | Clinical case reports and clinical practice | ECE2010

Approaches to the diagnosis and management of primary hyperparathyroidism in Europe results from a European Survey in five countries

Ralston Stuart , Langdahl Bente

Background: Primary hyperparathyroidism (PHPT) is a common condition, which in some patients can lead to complications such as osteoporosis and renal stones. This survey investigated diagnosis and treatment strategies for PHPT across Europe.Methods: The survey was conducted in five European countries (France, Germany, UK, Italy and Spain). 286 of the 421 interviewed physicians were endocrinologists; the remainder were rheumatologists (46), internists (50...

ea0063gp22 | Calcium and Bone 1 | ECE2019

OFELIA – Prevalence of osteoporosis in fragility fracture patients

Tei Randi , Plana-Ripoll Oleguer , Brink Ole , Langdahl Bente

Worldwide, a care gap has been recognized between presenting with a fragility fracture and prevention of the next fracture. Fracture Liaison Service is the most cost-effective method to close this gap, but its implementation is sparse in many countries. To assess the need for a subsequent fracture prevention program in Denmark, we conducted a cross-sectional study – named OFELIA - aiming to estimate the prevalence of osteoporosis in a Danish cohort of fragility fracture p...

ea0011p865 | Thyroid | ECE2006

Thyrotoxicosis – a risk factor for subsequent development of osteoporosis?

Zimmermann-Belsing Tina , Langdahl Bente , Charles Peder , Feldt-Rasmussen Ulla

Purpose: Thyrotoxic patients have an increased bone turnover and decreased Bone Mineral Density (BMD) at diagnosis. During antithyroid drug treatment (ATD) the patients improved their BMD but earlier studies have not been able to determine if BMD normalize or how long it will take.Methods: We have prospectively examined 32 females (approved by Danish Ethical Committee) with newly diagnosed Graves’ disease (antilog10, mean age (CI 95%)): 39 years (34...